Henseler Olaf, Heiden Margarethe, Haschberger Birgit, Hesse Janina, Seitz Rainer
Paul-Ehrlich-lnstitut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel, Langen, Germany.
Transfus Med Hemother. 2011;38(3):199-216. doi: 10.1159/000328949. Epub 2011 May 13.
This report contains the data collected in 2008 and 2009, pursuant to Section 21 German Transfusion Act as well as an overview of the supply situation during the last 10 years. In 2009, blood donation services reported a total of 7.5 million donations - the largest amount since 2000. At the same time, more than 4.7 million red blood cell (RBC) concentrates and more than 500,000 platelet concentrates were available. The number of therapeutic single plasma units decreased to 1.1 million units in 2009. The loss rate for RBC concentrates is still between 3 and 4% for the users while for the manufacturers it has decreased slightly to 1.4%. The loss rate, for platelet concentrates, on the other hand, increased in 2009, especially-what is noteworthy-for manufacturers of pooled platelet concentrates. The loss rate for apheresis platelet concentrates accounted for 5.2% compared to 17.5% for pooled platelet concentrates. As far as the users were concerned, loss rates for platelet concentrates largely remained unchanged with rates between 5 and 6%. Based on the data collected, the supply with blood components for transfusion can be regarded as assured. Nearly 2.9 million 1 of plasma for fractionation were collected in Germany in 2009. According to reports from the pharmaceutical industry, out of these, 2.6 million 1 remained on the German market, out of which only 56% were fractionated in this country. Many plasma derivatives are not manufactured in Germany, despite the large amounts of plasma collected. The supply with these products, however, is assured by imports. Overall, 16,409 autologous and 9,435 allogeneic stem cell preparations were manufactured in 2009, out of which 3,382 allogeneic preparations were exported. 3,181 autologous and 2,374 allogeneic preparations were transplanted; 187 of these products from imports. The large number of exported stem cells and the small number of imported ones suggest that no serious shortages are to be expected for the supply with these products.
本报告包含了依据德国《输血法》第21条在2008年和2009年收集的数据,以及过去十年的供应情况概述。2009年,献血服务机构报告的献血总量达750万次,为2000年以来的最高值。与此同时,有超过470万单位的红细胞浓缩物和超过50万单位的血小板浓缩物可供使用。2009年,治疗用单采血浆单位数量降至110万单位。红细胞浓缩物对用户的损耗率仍在3%至4%之间,而对制造商而言,该损耗率已略有下降至1.4%。另一方面,2009年血小板浓缩物的损耗率有所上升,尤其值得注意的是,对于混合血小板浓缩物的制造商来说。单采血小板浓缩物的损耗率为5.2%,而混合血小板浓缩物的损耗率为17.5%。就用户而言,血小板浓缩物的损耗率基本保持不变,在率5%至6%之间。根据收集到的数据,输血用血液成分的供应可视为有保障。2009年,德国采集了近290万升用于分离的血浆。根据制药行业的报告,其中260万升留在了德国市场,其中只有56%在该国进行了分离。尽管采集了大量血浆,但许多血浆衍生物并非在德国生产。不过,这些产品的供应通过进口得以保障。2009年,共生产了16409份自体和9,435份异体干细胞制剂,其中3,382份异体制剂出口。3,181份自体和2,374份异体制剂进行了移植,其中187份产品为进口产品。大量干细胞出口以及少量进口表明,预计这些产品的供应不会出现严重短缺。